Drug-Utilization, Healthcare Facilities Accesses and Costs of the First Generation of JAK Inhibitors in Rheumatoid Arthritis

Drug-Utilization, Healthcare Facilities Accesses and Costs of the First Generation of JAK Inhibitors in Rheumatoid Arthritis

This study is aimed at describing tofacitinib and baricitinib users by characterizing their prescription and healthcare histories, drug and healthcare utilization patterns, and direct costs from a healthcare system perspective. This retrospective cohort study was performed using Tuscan administrativ...

Full description

Bibliographic Details
Main Authors: Irma Convertino, Valentina Lorenzoni, Rosa Gini, Giuseppe Turchetti, Elisabetta Fini, Sabrina Giometto, Claudia Bartolini, Olga Paoletti, Sara Ferraro, Emiliano Cappello, Giulia Valdiserra, Marco Bonaso, Corrado Blandizzi, Marco Tuccori, Ersilia Lucenteforte
Format: Article
Language:English
Published: MDPI AG 2023-03-01
Series:Pharmaceuticals
Subjects:
JAK inhibitors
tofacitinib
baricitinib
rheumatoid arthritis
drug-utilization
cost
Online Access:https://www.mdpi.com/1424-8247/16/3/465

Internet

https://www.mdpi.com/1424-8247/16/3/465

Similar Items